Dupixent is already approved to treat a range of inflammatory diseases including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, making $6 billion in global sales last ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

Eczema-like rashes can sometimes be caused by infectious ... In some cases, they can radically improve symptoms. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...